Gilead Sciences has acquired biotech company XinThera in an effort to bolster its oncology and inflammation pipeline.
The acquisition will give Gilead Sciences access to XinThera’s portfolio of two small molecule inhibitor programmes, one of which targets PARP1 to treat cancer and the other of which targets MK2 for inflammatory diseases.
XinThera’s therapy targeting MK2 is expected to enter clinical trials later in 2023.
Gilead Sciences stated that the two programmes have the potential to address a number of indications and to provide development opportunities both alone and along with its wider portfolio.
By adding an additional pipeline targeting oncology and inflammation diseases, the company expects that the deal will complement its existing clinical development priorities.
Gilead Sciences research executive vice-president Flavius Martin stated: “The team at XinThera has developed research assets with the potential to target the DNA damage repair pathway in treating cancer and direct the body’s immune response in inflammatory diseases, both of which may improve outcomes for people living with these diseases.
“Guided by our scientific framework, this acquisition will allow us to further expand our early pipeline of diverse assets that will continue to fuel our durable late-phase portfolio.”
The financial terms of the deal were not disclosed by the companies.
Earlier this month, the European Medicines Agency’s (EMA) committee for medicinal products for human use (CHMP) recommended full marketing authorisation (MA) for Gilead Sciences’ Hepcludex (bulevirtide) for chronic hepatitis delta virus (HDV) and compensated liver disease treatment in adults.